Akari Therapeutics Plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Akari Therapeutics Plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.30M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($19.79M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($10.01M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($17.75M) | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | ($45.32M) | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | ($1.95M) | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | ($3.62M) | Feb 11, 2015 |
| FY2014 | Dec 31, 2012 | ($4.27M) | Feb 11, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.28M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($21.64M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($16.81M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($23.09M) | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | ($30.58M) | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | ($1.92M) | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | ($3.61M) | Feb 11, 2015 |
| FY2014 | Dec 31, 2012 | ($3.67M) | Feb 11, 2015 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.82M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.98M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.45M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $9.56M | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | $5.80M | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $1.62M | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | $1.28M | Feb 11, 2015 |
| FY2014 | Dec 31, 2012 | $1.48M | Feb 11, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.28M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.66M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $11.36M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $13.53M | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | $5.50M | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $303.1K | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | $2.33M | Feb 11, 2015 |
| FY2014 | Dec 31, 2012 | $2.18M | Feb 11, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.57M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($12.55M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($16.43M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($21.50M) | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | ($4.97M) | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | ($1.48M) | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | ($5.45M) | Feb 11, 2015 |
| FY2014 | Dec 31, 2012 | ($2.13M) | Feb 11, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $10.6K | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $0 | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Feb 11, 2015 |
| FY2014 | Dec 31, 2012 | $0 | Feb 11, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.89M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $50.56M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.36M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $13.83M | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | $69.89M | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $3.39M | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | $7.83M | Feb 11, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.56M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $28.33M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.58M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $12.04M | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | $21.17M | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $1.17M | Mar 23, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.33M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.23M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | ($229.0K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $1.79M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $5.56M | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | $48.72M | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $2.22M | Mar 23, 2016 |
| FY2015 | Dec 31, 2013 | $400.7K | Mar 23, 2016 |
| FY2014 | Dec 31, 2012 | ($3.36M) | Feb 11, 2015 |
| FY2014 | Dec 31, 2011 | ($2.49M) | Feb 11, 2015 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.43M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.43M | Mar 30, 2026 |
| FY2015 | Sep 18, 2015 | $19.28M | Mar 23, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($264.55M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($247.25M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($227.46M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($217.45M) | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | ($56.80M) | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | ($11.48M) | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | ($20.54M) | Feb 11, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.85M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $13.25M | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | $68.92M | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | $3.33M | Mar 23, 2016 |
| FY2015 | Dec 31, 2013 | $553.7K | Mar 23, 2016 |
| FY2014 | Dec 31, 2012 | $1.10M | Feb 11, 2015 |
| FY2014 | Dec 31, 2011 | $6.0K | Feb 11, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90.54B | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 53.19B | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 13.23B | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 7.44B | Mar 29, 2024 |
| FY2015 | Dec 31, 2015 | 1.18B | Mar 23, 2016 |
| FY2015 | Dec 31, 2014 | 722.35M | Mar 23, 2016 |
| FY2014 | Dec 31, 2013 | 40.23M | Feb 11, 2015 |